MetaCap

Damora Therapeutics (DMRA) vs Nurix Therapeutics (NRIX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Damora Therapeutics (DMRA) has outperformed Nurix Therapeutics (NRIX) over the past year, gaining 38.5% versus a loss of 23.3%. Over five years, NRIX leads with a -57.3% price change compared with -68.8% for DMRA. Damora Therapeutics is the larger company by market cap ($1.44 billion vs $1.40 billion), about 1.0 times the size.

On valuation, Nurix Therapeutics trades at a lower trailing P/E (5.3x vs 13.6x for Damora Therapeutics).

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

DMRA+38.46%NRIX-23.33%
+110%+40%-30%
Nov 21, 20251 yearNov 20, 2026
DMRA-69.04%NRIX-59.00%
+15%-44%-102%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

DMRA versus NRIX key metrics
MetricDMRANRIX
Share price$23.22$12.85
Market cap$1.44B$1.40B
1-day change-4.44%-5.55%
YTD return+0.91%-32.26%
1-year return+38.46%-23.33%
5-year return-68.83%-57.25%
P/E ratio (TTM)13.585.29
EPS (TTM)$1.71$2.43
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$83.98M
Revenue growth (YoY)—+53.95%
Net income (latest FY)$-209.84M$-264.46M
Operating margin—-340.16%
Net margin—-314.90%
52-week high$38.33$28.23
52-week low$15.76$12.83
Distance from 52-week high-39.41%-54.50%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+101.46%+160.80%
Average volume584.28K2.47M
Shares outstanding61.90M109.25M
Employees7317
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • DMRA has outperformed NRIX by 61.8 percentage points over the past year.
  • Damora Therapeutics trades at a higher earnings multiple (13.6x vs 5.3x trailing P/E).

About Damora Therapeutics

DMRA stock →

Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients.

Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees

About Nurix Therapeutics

NRIX stock →

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, which is in Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor that is in Phase 1a/1b clinical trials to treat immuno-oncology indications.

Health Care · Biotechnology: Pharmaceutical Preparations · 317 employees

DMRA vs NRIX FAQ

Which is bigger, Damora Therapeutics or Nurix Therapeutics?

Damora Therapeutics (DMRA) is larger, with a market capitalization of $1.44B compared with $1.40B for Nurix Therapeutics (NRIX).

Which stock has performed better over the past year, DMRA or NRIX?

DMRA returned +38.46% over the past 12 months, compared with -23.33% for NRIX (price return, excluding dividends). Past performance does not predict future results.

Which has the lower P/E ratio, DMRA or NRIX?

NRIX has the lower trailing P/E at 5.3, versus 13.6 for DMRA. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.

Are Damora Therapeutics and Nurix Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons